Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Liabilities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $29000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed 0.0% to $29000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $29000.0, a 0.0% change, with the full-year FY2024 number at $29000.0, changed 0.0% from a year prior.
  • Other Non-Current Liabilities was $29000.0 for Q3 2025 at Centessa Pharmaceuticals, roughly flat from $29000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $43000.0 in Q3 2022 to a low of $29000.0 in Q4 2023.
  • A 4-year average of $30555.6 and a median of $29000.0 in 2023 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 0.0% in 2024; the steepest drop was 0.0% in 2024.
  • Centessa Pharmaceuticals' Other Non-Current Liabilities stood at $43000.0 in 2022, then crashed by 32.56% to $29000.0 in 2023, then changed by 0.0% to $29000.0 in 2024, then changed by 0.0% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Other Non-Current Liabilities are $29000.0 (Q3 2025), $29000.0 (Q2 2025), and $29000.0 (Q1 2025).